Neuropace, Inc. Share Price Today. As of 3 November 2026, Neuropace, Inc.'s share price is $12.32. The stock opened at $12.42, compared to its previous close of $12.28. During tod ...

On November 3, both indices ended at their respective intraday highs, with the SENSEX rising by 1,225.07 points or 1.62% to close at 76,917.85. Meanwhile, the NIFTY50 ended higher by 370.05 points or ...

State Bank of India (SBI) reported a standalone net profit of ₹23,037.95 crore in Q2 FY27, registering a 14.3% YoY growth from ₹20,159.67 crore in the corresponding period last year.

State Bank of India's net interest income (NII) went up by 14.69% to ₹49,142.85 crore in Q2 FY27, compared to ₹42,847 crore in the same period of the previous fiscal year.

As of September 30, Solar Industries' order book stood at ₹20,178 crore, providing visibility for future execution, the company said. Following the earnings, Solar Industries India shares rallied 7% ...

India's gold demand declined 29% year-on-year to 162.5 tonnes in the September quarter as elevated domestic prices continued to weigh on affordability, even as the value of purchases rose 3% to ₹2.42 ...

The rally in IndiGo shares can also be attributed to easing crude oil prices, which were trading around $106 per barrel in the afternoon session.

Check gold and silver rates today, November 3, across major Indian cities. MCX gold falls 1.17% and silver drops 3.2% ahead of Dhanteras.

SBI Research has proposed doubling the savings account interest tax exemption to ₹20,000 and introducing a flat 15% tax rate ...

During the July-September quarter of FY27, Bajaj Finserv's revenue from operations increased by 16.66% year-on-year to ₹43,415.65 crore, from ₹37,214.56 crore in the corresponding quarter of the ...

Where the final orders passed on conclusion of the inquiry treat the suspension period as duty or leave for which leave salary is payable, contributions are to be recomputed on the emoluments the ...

In Q2 FY27, the company invested ₹111 crore in research and development (R&D), accounting for around 4% of its revenue. The pharma major’s revenue from operations grew 24% to ₹2,820 crore in the ...